Home | Welcome to Contract Pharma   
Last Updated Monday, May 20 2013
Print

Evotec, U.S. EPA in Compound Tox Pact



Published May 4, 2012
Related Searches: Industry News Toxicology
Evotec AG has entered into a five-year compound management agreement with the U.S. EPA. The contract has a total value of as much as $10 million.

Evotec, through its San Francisco operations, will provide chemical procurement, analysis, sample preparation, and management services to support the EPA’s National Computational Center for Toxicology (NCCT). Services provided will support bioactivity profiling of the EPA’s ToxCast (Prioritization of Environmentally Relevant Chemicals) Compound Library.

Dr. Mario Polywka, chief operating officer of Evotec, said, “We are very pleased that the U.S. EPA has again chosen Evotec to manage its compound collection in support of the NCCT. This follows from our initial contract with the EPA signed in 2007. Providing key, efficient scientific infrastructures such as compound management is a key element of Evotec Execute and we look forward to supporting the EPA’s ongoing effort to predict potential toxicity of environmental chemicals. This contract provides further long-term revenue and profitability for Evotec’s important compound management services in San Francisco which was acquired from BioFocus in 2011.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On